Discover CMTRA

a highly interactive forum...

Get Started

The Thirteenth Annual Meeting - POSTPONED


The MTCR 2020 conference has been postponed due to the COVID-19 Pandemic. Our next conference will be in Niagara by the Lake, July 18-22, 2021.

STAY TUNED FOR UPDATES.

About the Cancer Molecular Therapeutics Research Association
 

  • Provides a dynamic platform for the most contemporary and controversial approaches to the treatment of cancer

  • Dedicates half of the formal presentation time to questions and answers to promote rigorous discussion

  • Welcomes an active dialog among investigators from industry, academia, government and, foundations

  • Enables informal and intimate (150 participants) networking for graduate students, postdoctoral fellows, residents and, early-stage and established investigators

  • Awards the top four poster presenters with the opportunity to orally present their research and attend next year’s conference free of charge

  • Builds on the legacy of more than two decades of annual conference

 


 

CMTRA

Officers & Board Members

Peter Houghton, Ph.D.

President

Director| Greehey Children's Cancer Research Institute, UT Health at San Antonio, San Antonio, TX 78229 - USA

Robert Kramer, Ph.D.

Vice President

Consultant to the Pharmaceutical & Biotechnology Industry, Newton, PA - USA

William J. Placzek, Ph.D.

Treasurer

Assistant Professor | Department of Biochemistry and Molecular Genetics; Director | Central Alabama High-Field NMR Facility; Co-Director | Structural Biology Shared Facility, Cancer Center, The University of Alabama at Birmingham - USA

James D Winkler, Ph.D.

Secretary

Vice President | FORMA Therapeutics - 500 Arsenal Street, Watertown, MA 02472 - USA

Emeratus: Alan Eastman, Ph.D.

Professor of Pharmacology

Director | Molecular Therapeutics Program - Geisel School of Medicine at Dartmouth, USA

Mary-Ann Bjornsti, Ph.D.

Board Member

Professor & Chair Newman H Waters Chair of Clinical Pharmacology | Department of Pharmacology & Toxicology, University of Alabama at Birmingha, USA

Phillip A. Dennis, M.D., Ph.D.

Board Member

VP, Disease Strategy Head, Lung Cancer Global Clinical Lead, Lung Cancer Immuno-Oncology - AstraZeneca,
1800 Concord Pike, Wilmington, DE 19803 - USA

Lori Friedman, Ph.D.

Board Member

Chief Scientific Officer | ORIC Pharmaceuticals,
240 E. Grand Avenue, South San Francisco, CA 94080 - USA

John A. Hickman, D.Sc.

Board Member

Agon Consulting, Paris -
126 Boulevard Pereire, 75017 Paris, France


John S. Lazo, Ph.D.

Board Member

Harrison Distinguished Professor |
Departments of Pharmacology and Chemistry,
University of Virginia, USA


Shiva Malek, Ph.D.

Board Member

Senior Director | Department of Discovery Oncology Adjunct Professor | Department of Biochemistry and Biophysics, School of Medicine, UCSF Genentech Inc. |
1 DNA Way | South San Francisco, CA 94080

Zahid H. Siddik, Ph.D.

Board Member

Professor of Medicine | Pharmacology Department of Experimental Therapeutics - MD Anderson Cancer Center,
1515 Holcombe Boulevard Unit 1950 Houston, TX 77030 - USA

Branimir I. Sikic, M.D.

Board Member

Director | Stanford Clinical & Translational Research Unit; Co-director | Stanford University Center for Clinical & Translational Education & Research (Spectrum) - Stanford University School of Medicine, Stanford, CA 94305 - USA

Susan Galbraith, Ph.D.

Board Member

Senior Vice President |
IMED Oncology,
AstraZeneca -
Cambridge Science Park, Cambridge,
United Kingdom

Eli M. Wallace, Ph.D.

Board Member

Chief Scientific Officer |
Peloton Therapeutics -
2330 Inwood Road, Suite 226,
Dallas, TX 75235-7323
- USA

Martin McMahon, Ph.D.

Board Member

Cumming-Presidential Professor | Cancer Biology & Senior Director | Preclinical Translation, Huntsman Cancer Institute & Dept. of Dermatology -
University of Utah, Salt Lake City,
UT 84112 USA

Annual Meetings

Programs

The Cancer Molecular Therapeutics Research Association [CMTRA] was created in 2008 to organize and host the annual Molecular Therapeutics of Cancer meeting. The meeting objective is to provide a forum for presentation and discussion of contemporary research in the field of cancer drug development and therapy. Modeled after small Gordon-type conferences, the meeting provides an opportunity for young and established researchers to discuss and challenge current paradigms for cancer drug development and therapy, as well as a venue where novel ideas can be presented with anticipation of lively debate.
 

2019 Conference

at Granlibakken Tahoe Resort & Conferenec Center, Lake Tahoe, CA
(Twelveth Meeting)

2018 Conference

at Sundance, Utah
(Eleventh Meeting)

2017 Conference

at Hilton Burlington Hotel, Burlington, Vermont
(Tenth Meeting)

2016 Conference

at University of Washington, Seattle, Washington
(Ninth Meeting)

2015 Conference

at Tufts University, Medford, Massachussetts
(Eighth Meeting)

2014 Conference

at Asilomar, Pacific Grove, Californias
(Seventh Meeting)

2013 Conference

at University of Colorado, Boulder, Colorado
(Sixth Meeting)

2012 Conference

at Princeton University
(Fifth Meeting)

2011 Conference

at The Asilomar Conference Center
(Fourth meeting)

2010 Conference

at The Asilomar Conference Center
(Third meeting)

2009 Conference

at Stanford University
(Second meeting)

2008 Conference

at Princeton University
(First meeting)
 

Contact Us

Victor Aguilar

Greehey Children's Cancer Research Institute,
UT Health San Antonio

8403 Floyd Curl Drive, MSC 7784
San Antonio, TX 78229

210.562.9161

210.562.9014

aguilarv@uthscsa.edu